OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results